If you read my post more closely you will see that concerns would need to be alleviated for the drug to go to first or second line. I don't hear any clinicians saying they want it front line or would be comfortable with front line. I didn't say they have concerns using it under its current indication! However, given that the AEs continue to be significant and other drugs such as gleevac are very well tolerated it will not move to earlier indications until as I said in my previous post.
Market Data 
Markets 
AI
